Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Total Liabilities: 2017-2025

Historic Total Liabilities for Autolus Therapeutics (AUTL) over the last 6 years, with Sep 2025 value amounting to $396.5 million.

  • Autolus Therapeutics' Total Liabilities rose 13.11% to $396.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $396.5 million, marking a year-over-year increase of 13.11%. This contributed to the annual value of $355.4 million for FY2024, which is 34.67% up from last year.
  • Autolus Therapeutics' Total Liabilities amounted to $396.5 million in Q3 2025, which was up 5.87% from $374.5 million recorded in Q2 2025.
  • Autolus Therapeutics' 5-year Total Liabilities high stood at $396.5 million for Q3 2025, and its period low was $47.0 million during Q2 2021.
  • Its 3-year average for Total Liabilities is $309.2 million, with a median of $325.8 million in 2024.
  • Within the past 5 years, the most significant YoY rise in Autolus Therapeutics' Total Liabilities was 143.92% (2021), while the steepest drop was 35.33% (2021).
  • Quarterly analysis of 5 years shows Autolus Therapeutics' Total Liabilities stood at $92.2 million in 2021, then skyrocketed by 107.72% to $191.6 million in 2022, then surged by 37.74% to $263.9 million in 2023, then skyrocketed by 34.67% to $355.4 million in 2024, then climbed by 13.11% to $396.5 million in 2025.
  • Its Total Liabilities stands at $396.5 million for Q3 2025, versus $374.5 million for Q2 2025 and $375.2 million for Q1 2025.